PYXS Pyxis Oncology Company Short-Term Debt

pyxisoncology.com - graphic logo of issuer PYXS

Pyxis Oncology, Inc. (PYXS) develops oncology treatments by stimulating the body's own immune defenses. This chart of the market price helps assess an asset whose success depends on the safety of new treatment methods and the availability of funding for trials. The indicator stands at 0.01. High research costs and strict regulatory oversight, combined with patent protection, create significant barriers to entry for new players.

PYXS Pyxis Short-Term Debt (07/04/2022 - 10/30/2026)

Analytical breakdowns and data insights for company Pyxis Oncology Inc. (PYXS)

- current quotes and average value forecast:
Price Chart Pyxis|PYXS - Average Forecast Price
- market capitalization data:
Market Value Pyxis Oncology, Inc.|PYXS - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Pyxis Oncology|PYXS - Total Stockholders' Equity|Market Capitalization to Book Value Ratio pyxisoncology.com|PYXS - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Pyxis Oncology, Inc.|PYXS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Pyxis|PYXS - Aggregate Debt Obligations|Debts to Book Capitalization Pyxis Oncology, Inc.|PYXS - Long-Term Debt Volume|Company Short-Term Debt Pyxis Oncology|Quick Liquidity pyxisoncology.com
- earnings and multiples data:
PYXS - Net Income
General company analysis:pyxisoncology.com (PYXS)
Flagship merchandise of Pyxis Oncology, Inc.

This metric is calculated as the sum of all liabilities with a maturity of up to one year. This indicator determines current liquidity and the issuer's ability to service short-term loans. For Pyxis Oncology, Inc. (PYXS), this is a critical marker of available capital for conducting costly clinical trials of anti-cancer drugs. Analyzing total short-term debt allows for an assessment of the risk of funding shortages before the completion of scientific trials. The trend in total short-term debt reveals the real financial stability of the company.

Competitors of Pyxis Oncology, Inc.

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt Zymeworks Inc.|Short-Term Debt tangotx.com TNGX|Company Short-Term Debts IOVA|Immatics NV (IMTX) - Short-Term Indebtedness|Xencor Corp - Company Current Liabilities|Compass Therapeutics Corp (CMPX) - Short-Term Debt|REPL: Company Current Liabilities|Company Short-Term Loans and Borrowings LYEL (lyell.com)|IPHA: Company Short-Term Debts|CGEN - Short-Term Debt Volume|Company Short-Term Debt IO Biotech Corp|Company Current Liabilities Sutro Biopharma, Inc (STRO)|Company Short-Term Debt MiNK Therapeutics, Inc. (INKT)|Company Current Liabilities werewolftx.com HOWL|Immix Biopharma - Company Current Liabilities|Company Short-Term Debts alxoncology.com ALXO|CUE - Company Short-Term Debt|PDSB (PDS Biotechnology) - Company Short-Term Indebtedness|sonnetbio.com (SONN) - Company Short-Term Debt|Short-Term Debt MAIABiotech.com (MAIA)|Company Current Liabilities LIMN|LVTX - Short-Term Indebtedness|Company Current Liabilities NXTC (NextCure Corp)|Amount of Current Liabilities LPTX|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)